Geron (GERN) Gets ODAC Votes for Blood Disorder Drug, Shares Up [Yahoo! Finance]
Geron Corporation (GERN)
Last geron corporation earnings: 3/12 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
geron.com/investors
Company Research
Source: Yahoo! Finance
pipeline candidate, imetelstat, for the treatment of transfusion-dependent (TD) anemia in adult patients with low-to-intermediate-1 risk myelodysplastic syndromes (LR-MDS) who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). The ODAC voted 12:2 in favor of imetelstat's benefits over risks. Consequently, shares of this late-stage clinical biopharmaceutical company have risen in pre-market trading. Imetelstat is a novel, first-in-class investigational telomerase inhibitor exclusively owned by Geron and is being developed for hematologic malignancies. The favorable decision by the ODAC was based on results from the phase III IMerge clinical trial. The primary endpoint of red blood cell transfusion independence (RBC-TI) for at least eight consecutive weeks was significantly higher with imetelstat as compared to placebo. Additionally, 28% of imetelstat-treated patients experienced a statistically significant improvemen
Show less
Read more
Impact Snapshot
Event Time:
GERN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GERN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GERN alerts
High impacting Geron Corporation news events
Weekly update
A roundup of the hottest topics
GERN
News
- Geron Co. (NASDAQ: GERN) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $5.00 price target on the stock.MarketBeat
- Geron (GERN) Reports Q1 Loss, Tops Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- Geron Corporation Reports First Quarter 2024 Financial Results and Business Highlights [Yahoo! Finance]Yahoo! Finance
- Geron Corporation Reports First Quarter 2024 Financial Results and Business HighlightsBusiness Wire
- Baird downgrades Geron to neutral, cites valuation concerns [Seeking Alpha]Seeking Alpha
GERN
Earnings
- 5/2/24 - Beat
GERN
Sec Filings
- 5/2/24 - Form 10-Q
- 5/2/24 - Form 8-K
- 3/27/24 - Form ARS
- GERN's page on the SEC website